Phase Space AI

Twist Bioscience

TWST · investment memo

Valuation margin
demonstrated − required CAGR
-3.2%
Required CAGR
26.0%
Demonstrated
22.8%
Terminal margin
20.0%
Exit multiple
33.1x
Company state
C
Terminal margin basis

GAAP EBIT margin. BACK-SOLVED from the scan's published required_cagr_pct - the scan does not persist terminal_margin, so this figure was reverse-engineered from an output, not derived per-name.

Risk & exit

Four distinct questions, one field each. A price is not a thesis: the trigger below forces a re-underwrite and freezes further purchases — it is never an automatic sell.

Risk trigger
23% below the memo price
$68.67
Forward E[R]
vs a 0% floor
-23.8%

A daily close below $68.67 triggers a mandatory re-underwrite and freezes further purchases. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Thesis-invalidation conditions

Not stated. This name has no falsifiable invalidation conditions on file, so it cannot be risk-monitored. That is a gap in the research, not a clean bill of health — recorded rather than hidden.

Impairment case

Not stated. No permanent-loss case with a named cause is on file. A valuation bear case is not an impairment case.

Documents

TWST Company Research TWST Valuation and Trade